Compare Centrus Energy Corp (LEU) vs TG Therapeutics Inc (TGTX) Price & Performance

Centrus Energy (LEU) trades at $142.44, down 3.19% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics (P/E 75.18, P/S 6.68) while profitability metrics remain solid (net margin 10.23%, ROE 8.05%). Recent news highlights the company's strategic position as a key HALEU supplier amid growing nuclear energy demand, with multiple new supply contracts announced in September 2026.

LEU presents a high-risk, high-reward opportunity with analyst consensus price target of $218.10 (53% upside) but significant execution risks. The company's growth depends on successful expansion of domestic uranium enrichment capacity and capitalizing on nuclear energy tailwinds, though recent profit margin compression and negative operating cash flow projections for 2026 warrant caution.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.